FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 361:737-740 August 20, 2009 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Rickee Rudowitz, a 56-year-old New Jersey woman with hypertension, believes that a generic version of long-acting metoprolol played havoc with her health last year. Rudowitz said her blood pressure had been well controlled for 3 years by Toprol XL, AstraZeneca's brand-name beta-blocker, but that it "went over the moon" when her pharmacy-benefits program switched her to a generic version in early 2008. "I started having headaches and a lot of shortness of breath," she recalled. Her doctor switched her back to the brand-name drug, she said, and her symptoms disappeared.

Grant Melocik had suspicions about the same product, Metoprolol ER, . . . [Full Text of this Article]

Source Information

Dr. Okie (susan.okie@verizon.net) is a national correspondent for the Journal.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2010 Massachusetts Medical Society. All rights reserved.